Mini review on emerging methods of preparation of liposome and its application as Liposome drug delivery systems
<p>Liposomes, sphere-shaped vesicles consisting of one or more phospholipid bilayers, were fi rst</p><p>described in the mid-60s. Nowadays, they are a very useful reproduction, reagent, and device in various</p><p>scientifi c disciplines, including medicine, chemistry,...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
Open Journal of Pharmacology and Pharmacotherapeutics - Peertechz Publications,
2018-10-26.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | <p>Liposomes, sphere-shaped vesicles consisting of one or more phospholipid bilayers, were fi rst</p><p>described in the mid-60s. Nowadays, they are a very useful reproduction, reagent, and device in various</p><p>scientifi c disciplines, including medicine, chemistry, biochemistry, colloid science, biology, physics,</p><p>biophysics, mathematics and theoretical. After the initial discoveries liposomes have made their way to</p><p>the market. Among numerous brilliant new drug delivery systems developed, liposomes characterize an</p><p>advanced technology to deliver active molecules to the site of action, and at present, several formulations</p><p>are in clinical use. Research on liposome technology has progressed from conventional vesicles to</p><p>'second-generation liposomes', in which long-circulating liposomes are obtained by modulating the lipid</p><p>composition, size, and charge of the vesicle. Liposomes with modifi ed surfaces have also been developed</p><p>using several molecules, such as glycolipids or sialic acid. This paper mini review summarizes exclusively</p><p>Nano-lipids, its applications in medicine scalable techniques in treating dreadful diseases cancer, AIDS,</p><p>paralysis etcand focuses on strengths, respectively, limitations in respect to industrial applicability and</p><p>regulatory requirements concerning liposomal drug formulations based on FDA and EMEA documents.</p> |
---|---|
DOI: | 10.17352/ojpp.000007 |